ENTERA BIO

Indonesia
Sumbul, North Sumatra, Indonesia, 91220

Company profile

ENTERA BIO company profile

Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience and networks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience.

Business identity

Contact email
[email protected]
Phone number
972-2-532-7151
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2010-01-01

Headquarters

Postal code
91220
Country code
ID
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$30.4M
Last funding
Post IPO Equity / $6.6M / 2023-12-26
Last equity funding
Post IPO Equity / $6.6M
Investors
2
Lead investors
1
Founders
1
Articles
132
Exited on
2018-06-29

Founders and investors

Founders

Dr. Phillip Schwartz

Lead investors

Pontifax

Investors

Intuitive Venture PartnersPontifax